Mylan launches cabergoline tablets

Drug used to treat hyperprolactinemic disorders

PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

 

Login or Register to post a comment.